Cravarezza P, Radaeli E, Toffoli C, Rigosa C
Acta Diabetol Lat. 1986 Oct-Dec;23(4):345-50. doi: 10.1007/BF02582068.
Residual B-cell function was assessed in 61 type I and 17 type II insulin-treated diabetics by measuring plasma C-peptide concentration before and after i.v. injection of 1 mg glucagon to evaluate a possible difference in response to the test in the two groups. Fasting and post-stimulatory C-peptide levels were significantly higher in type II diabetics than in type I (0.45 +/- 0.25 vs 0.12 +/- 0.10 nmol/l for basal IRCP, 0.39 +/- 0.19 vs 0.06 +/- 0.11 nmol/l for delta IRCP, p less than 0.0001), but there was some overlap in individual values. Twenty-one percent of type I and 29% of type II diabetics had values in the overlap area. These percentages were reduced to 6% and 12%, respectively when only long-term (duration of diabetes more than five years) type I diabetics were considered. These data indicate that a glucagon test is useful to discriminate most type I diabetics from insulin-treated type II diabetics.
通过静脉注射1mg胰高血糖素前后测量血浆C肽浓度，评估了61例I型和17例II型胰岛素治疗糖尿病患者的残余B细胞功能，以评估两组对该试验反应的可能差异。II型糖尿病患者的空腹和刺激后C肽水平显著高于I型糖尿病患者（基础IRCP分别为0.45±0.25 vs 0.12±0.10nmol/L，δIRCP分别为0.39±0.19 vs 0.06±0.11nmol/L，p<0.0001），但个体值存在一定重叠。21%的I型糖尿病患者和29%的II型糖尿病患者的值处于重叠区域。仅考虑长期（糖尿病病程超过五年）I型糖尿病患者时，这些百分比分别降至6%和12%。这些数据表明，胰高血糖素试验有助于区分大多数I型糖尿病患者和胰岛素治疗的II型糖尿病患者。
